Background The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT)
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …

Despite advances in the treatment of glioblastoma (GBM), median survival is 12–15 months.
O 6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is …

Aim: MGMT promoter methylation has been associated with improved survival in
glioblastoma multiforme treated with temozolomide. However, there is no consensus on …

Many patients with malignant gliomas do not respond to alkylating agent chemotherapy.
Alkylator resistance of glioma cells is mainly mediated by the DNA repair enzyme O 6 …

Hypermethylation in the promoter region of the MGMT gene encoding the DNA repair
protein O6-methylguanine-DNA methyltransferase is among the most important prognostic …

Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The
identification of novel molecular prognostic markers of GBM has recently been an area of …

Background Glioblastoma is an aggressive form of brain cancer. Approximately five in 100
people with glioblastoma survive for five years past diagnosis. Glioblastomas that have a …

Promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene plays
a role in cellular response to alkylating agents. In the present study aimed to:(i) evaluate the …

Abstract O 6-Methylguanine DNA methyltransferase (MGMT) is implicated as a major
predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of …